1	3 Male and female patients will be eligible for enrollment Females should be either of nonchildbearing potential as a result of surgery or menopause 1 year after onset or of childbearing potential and practicing a medically acceptable method of contraception e.g. abstinence a barrier method plus spermicide|spermicide[297,307]||||||||||9969|9969|spermicide
2	or intrauterine device IUD for at least 1 month before Visit 1 Screening and for 1 month after the end of the study They must also have a negative serum beta-human chorionic gonadotropin B-hCG at Screening Those females using hormonal contraceptives must also be using an additional approved method|hCG[497,500]||intrauterine device[311,330]|||||1 month[348,355]||C1141639|340705|340705|chorionic gonadotropin, human
3	of contraception e.g. a barrier method plus spermicide or IUD starting with the Baseline Phase and continuing throughout the entire study period|spermicide[651,661]||||||||||9969|9969|spermicide
